Japanese Pharmacology & Therapeutics（JPT）
Vol. 30 Suppl.2 2002
Opening Remarks
H. Kawasaki
Jpn Pharmacol Ther 2002 30（s2）289
The influence of radiofrequency ablation on liver parenchymal function in patients with hepatocellular carcinoma
M. Koda, et al.
Jpn Pharmacol Ther 2002 30（s2）295
SH. Kawa
Jpn Pharmacol Ther 2002 30（s2）301
Effect of late evening snack composed of a special amino acid preparation on liver cirrhosis
C. Koreeda, et al.
Jpn Pharmacol Ther 2002 30（s2）307
Association between chronic hepatitis C virus infection and insulin resistance
M. Furutani, et al.
Jpn Pharmacol Ther 2002 30（s2）313
【Discussion 1～4】
Jpn Pharmacol Ther 2002 30（s2）317
Significance of serum thioredoxin in interferon therapy for chronic hepatitis type C
A. Hirohama, et al.
Jpn Pharmacol Ther 2002 30（s2）319
Clinical usefulness of plasma matrix metalloproteinase（MMP）－9（gelatinase B）assay in comparison with plasma MMP－2（gelatinase A）assay in patients with chronic liver disease and with hepatocelluar carcinoma
K. Mimura, et al.
Jpn Pharmacol Ther 2002 30（s2） 323
Serum PAF－acetylhydrolase（PAF－AH）in hepatobiliary disease
T. Ito, et al.
Jpn Pharmacol Ther 2002 30（s2）331
【Discussion 5～7】
Jpn Pharmacol Ther 2002 30（s2）335
Effect of a 72 kDa heat shock protein to endotoxemia in the carbon tetrachloride－induced fibrotic rat liver
K. Mikami, et al.
Jpn Pharmacol Ther 2002 30（s2） 337
Bio－imaging of nitric oxide－producing cells in slices of rat liver using 4,5－diaminofluorescein
T. Kono, et al.
Jpn Pharmacol Ther 2002 30（s2）339
The inhibitory effect of TIMP－1 on the spontaneous liver fibrosis resolution in a transgenic mouse model
H. Yoshiji, et al.
Jpn Pharmacol Ther 2002 30（s2）343
【Discussion 8～10】
Jpn Pharmacol Ther 2002 30（s2）349
Usefulness of caffeine test in predicting hepatic injury induced by flutamide
S. Ozono, et al.
Jpn Pharmacol Ther 2002 30（s2）353
Assessment of the diagnostic scale of the internal consensus meeting with cases of drug induced liver injury in our department
Y. Takamori, et al.
Jpn Pharmacol Ther 2002 30（s2）357
Genotypic－phenotypic discordance possibility（“phenocopy”）of cytochrome P450（CYP）2C19 and 2D6 in ordinary clinical settings
I. Ieiri, et al.
Jpn Pharmacol Ther 2002 30（s2）361
【Discussion 11～14】
Jpn Pharmacol Ther 2002 30（s2）367
Effect of NSAIDs on concanavalin A－induced liver injury in mice
S. Okamoto, et al.
Jpn Pharmacol Ther 2002 30（s2）369
Effect of a hyaluronan on concanavalin A－induced liver injury in mice
K. Nakamura, et al.
Jpn Pharmacol Ther 2002 30（s2）373
The role of macrophage inflammatory protein－1α on concanavarin A induced liver injury in mice
S. Yokohama, et al.
Jpn Pharmacol Ther 2002 30（s2）379
【Discussion 15～17】
Jpn Pharmacol Ther 2002 30（s2）383
A case of erythropoietic protoporphyria with severe cholestasis
T. Yamamoto, et al.
Jpn Pharmacol Ther 2002 30（s2）385
Disappearance of bilirubin and bile acid in patients with PTCD
Y. Kawazoe, et al.
Jpn Pharmacol Ther 2002 30（s2）393
A unique inhibition of cholesterol crystallization under biliary infection
K. Nakai, et al.
Jpn Pharmacol Ther 2002 30（s2）397
Inhibition of bile salt－induced apoptosis by cytoprotective bile salts and lecithin species in bile duct epithelium
D. Komichi, et al.
Jpn Pharmacol Ther 2002 30（s2）399
【Discussion 18～21】
Jpn Pharmacol Ther 2002 30（s2）401
Urinary excretion of pravastatin and temocapril in bile－duct ligated rats and EHBR
Y. Takada, et al.
Jpn Pharmacol Ther 2002 30（s2）405
Biliary excretion of an angiotensin II receptor antagonist, RNH－6270
M. Hojo, et al.
Jpn Pharmacol Ther 2002 30（s2）409
Sinusoidal efflux of bile acid via multidrug resistance associated protein 3（Mrp3）
H. Akita, et al.
Jpn Pharmacol Ther 2002 30（s2）413
Comparative functional analysis of human OATP2 and OATP8
K. Maeda, et al.
Jpn Pharmacol Ther 2002 30（s2）417
【Discussion 22～25】
Jpn Pharmacol Ther 2002 30（s2）421
Inhibition on the transporter－mediated hepatic uptake as a mechanism of drug－drug interaction
Y. Shitara, et al.
Jpn Pharmacol Ther 2002 30（s2）425
Transport of sulfated conjugates by human breast cancer resistance protein（BCRP／ABCG2）
M. Suzuki, et al.
Jpn Pharmacol Ther 2002 30（s2）433
Role of hepatic organic cation transporter 1（Oct1）in the lactic acidosis caused by biguanide compounds
H. Kusuhara, et al.
Jpn Pharmacol Ther 2002 30（s2）437
Estimation of a double-transfectanted MDCK II monolayer co-expressing human OATP2 and MRP2
―In order to quantitatively estimate the property of transcellular transport of cerivastatin in human liver―
S. Matsushima, et al.
Jpn Pharmacol Ther 2002 30（s2）441
Enhanced expression of endothelial nitric oxide synthase and caveolin-1 in human cirrhosis
H. Yokomori, et al.
Jpn Pharmacol Ther 2002 30（s2）445
【Discussion 26～30】
Jpn Pharmacol Ther 2002 30（s2）449
Closing Remarks
N. Kitami
Jpn Pharmacol Ther 2002 30（s2）453